Stockwatch: Tax inversions - gotta love 'em
This article was originally published in Scrip
Executive Summary
Somewhere between North Carolina and Dublin, there might be a tree carved with the names of the two star-crossed companies that announced their merger last week. But paraphrasing Shakespeare's Romeo and Juliet, the course of true mergers never did run smooth and behind last week's latest specialty pharmaceutical tax inversion probably lies a more Machiavellian love triangle.